CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
Phase of Trial: Phase I/II
Latest Information Update: 31 Aug 2016
At a glance
- Drugs CART 30 (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 31 Aug 2016 Results from Phase I part of this trial (n=18) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 22 May 2015 According to a Cellular Biomedicine media release, data from this study were presented at the 10th Annual World Stem Cells & Regenerative Medicine Congress 2015.
- 22 May 2015 Results published in a Cellular Biomedicine media release.